Please note: the original posting of this opportunity had an internal deadline of March 14, 2023. This has been adjusted to March 13th to accommodate Mid-March break.
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an expert review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.
For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program.
Date RFP Issued: January 19, 2023
Geographic Scope: All countries except for the United States
Specific Area of Interest: Pfizer is interested in supporting research proposals that advance our understanding of the epidemiology, basic science and early diagnosis and treatment of ATTR amyloidosis through research focused in the following areas:
Epidemiologic evaluations for ATTR amyloidosis
Approaches for the early identification and follow up of ATTR amyloidosis patients
RW efficacy and safety of tafamidis in the clinical setting for the management of ATTR amyloidosis
Evaluation of patients with ATTR-CM presenting with a mixed phenotype (e.g. cardiomyopathy and polyneuropathy)